Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluate the efficacy of Insulin Glargine Injection (HS004) in the treatment of diabetes compared with Lantus®
CTR20171016Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Aug 2017; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20171016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171016.